Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Most organizations can afford a 10% efficiency cut, providing immediate financial relief, but how these cuts are done often ...

BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.

X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

The stock's fall snapped a seven-day winning streak.

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Layoffs are a fact of life in the pharma and biotech industries with companies frequently adjusting headcount as their priorities shift. But the steady stream of cuts grew stronger last year as ...